MLchartDataset catalogue

pan-RAF/MEK molecular glue NST-628

Term · Oncology and biomedicine · MLC-T-ONC-015816

An orally bioavailable non-covalent non-degrading pan-RAF/mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) dual molecular glue, with potential antineoplastic activity. Upon oral administration, pan-RAF/MEK molecular glue NST-628 targets and glues A-RAF, B-RAF and C-RAF protein kinases with unphosphorylated MEK1, forming a stable and inactive RAF-MEK complex. This prevents the phosphorylation and activation of MEK by RAF, inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. Oncogenic mutations in RAF plays a key role in the overactivation of the RAS-mitogen-activated protein kinase (MAPK) pathway and drives tumor cell proliferation and survival. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations. NST-628 is able to cross the blood-brain barrier (BBB).

Table 1. Record
IdentifierMLC-T-ONC-015816
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015816",
  "term": "pan-RAF/MEK molecular glue NST-628",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable non-covalent non-degrading pan-RAF/mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) dual molecular glue, with potential antineoplastic activity. Upon oral administration, pan-RAF/MEK molecular glue NST-628 targets and glues A-RAF, B-RAF and C-RAF protein kinases with unphosphorylated MEK1, forming a stable and inactive RAF-MEK complex. This prevents the phosphorylation and activation of MEK by RAF, inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. Oncogenic mutations in RAF plays a key role in the overactivation of the RAS-mitogen-activated protein kinase (MAPK) pathway and drives tumor cell proliferation and survival. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations. NST-628 is able to cross the blood-brain barrier (BBB).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pan-raf-mek-molecular-glue-nst-628/"
}

Record 12,609 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.